Literature DB >> 31376426

Targeting the transferrin receptor for brain drug delivery.

Kasper Bendix Johnsen1, Annette Burkhart2, Louiza Bohn Thomsen2, Thomas Lars Andresen3, Torben Moos2.   

Abstract

Obtaining efficient drug delivery to the brain remains the biggest challenge for the development of therapeutics to treat diseases of the central nervous system. The main obstacle is the blood-brain barrier (BBB), which impedes the entrance of most molecules present in the systemic circulation, especially large molecule drugs and nanomedicines. To overcome this obstacle, targeting strategies binding to nutrient receptors present at the luminal membrane of the BBB are frequently employed. Amongst the numerous potential targets at the BBB, the transferrin receptor (TfR) remains the most common target used to ensure sufficient drug delivery to the brain. In this review, we provide a full account on the use of the TfR as a target for brain drug delivery by describing the function of the TfR in the BBB, the historical background of its use in drug delivery, and the most recent evidence suggesting TfR-targeted medicines to be efficient for brain drug delivery with a clear clinical potential.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody; Brain drug delivery; Nanoparticle; Transcytosis; Transferrin receptor

Year:  2019        PMID: 31376426     DOI: 10.1016/j.pneurobio.2019.101665

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  49 in total

1.  The blood-brain barrier studied in vitro across species.

Authors:  Maj Schneider Thomsen; Nanna Humle; Eva Hede; Torben Moos; Annette Burkhart; Louiza Bohn Thomsen
Journal:  PLoS One       Date:  2021-03-12       Impact factor: 3.240

2.  Caveolae-Mediated Transport at the Injured Blood-Brain Barrier as an Underexplored Pathway for Central Nervous System Drug Delivery.

Authors:  Alexander G Sorets; Jonah C Rosch; Craig L Duvall; Ethan S Lippmann
Journal:  Curr Opin Chem Eng       Date:  2020-09-12       Impact factor: 5.163

3.  Transferrin Receptor-Targeted PEG-PLA Polymeric Micelles for Chemotherapy Against Glioblastoma Multiforme.

Authors:  Ping Sun; Yue Xiao; Qianqian Di; Wenjing Ma; Xingyu Ma; Qingqing Wang; Weilin Chen
Journal:  Int J Nanomedicine       Date:  2020-09-11

Review 4.  The blood-tumour barrier in cancer biology and therapy.

Authors:  Patricia S Steeg
Journal:  Nat Rev Clin Oncol       Date:  2021-07-12       Impact factor: 66.675

5.  Distributions of intravenous injected iodine nanoparticles in orthotopic u87 human glioma xenografts over time and tumor therapy.

Authors:  Sharif M Ridwan; Ferris El-Tayyeb; James F Hainfeld; Henry M Smilowitz
Journal:  Nanomedicine (Lond)       Date:  2020-09-25       Impact factor: 5.307

Review 6.  Targeting NRF2 to suppress ferroptosis in brain injury.

Authors:  Shunchen Song; Yaxuan Gao; Yi Sheng; Tongyu Rui; Chengliang Luo
Journal:  Histol Histopathol       Date:  2020-11-26       Impact factor: 2.303

7.  Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB).

Authors:  Hans Christian Cederberg Helms; Mie Kristensen; Lasse Saaby; Gert Fricker; Birger Brodin
Journal:  Handb Exp Pharmacol       Date:  2022

8.  Brain Distribution of Drugs: Pharmacokinetic Considerations.

Authors:  Irena Loryan; Margareta Hammarlund-Udenaes; Stina Syvänen
Journal:  Handb Exp Pharmacol       Date:  2022

9.  Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size.

Authors:  Rebecca Faresjö; Gillian Bonvicini; Xiaotian T Fang; Ximena Aguilar; Dag Sehlin; Stina Syvänen
Journal:  Fluids Barriers CNS       Date:  2021-06-02

10.  Incorporation of docosahexaenoic acid (DHA) enhances nanodelivery of antiretroviral across the blood-brain barrier for treatment of HIV reservoir in brain.

Authors:  Pengbo Guo; Mengjie Si; Di Wu; Hui Yi Xue; Wenhui Hu; Ho Lun Wong
Journal:  J Control Release       Date:  2020-10-01       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.